These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 9746770

  • 1. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
    Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A.
    Blood; 1998 Oct 01; 92(7):2322-33. PubMed ID: 9746770
    [Abstract] [Full Text] [Related]

  • 2. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
    Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, Hogge DE.
    Biol Blood Marrow Transplant; 2002 Oct 01; 8(8):435-43. PubMed ID: 12234169
    [Abstract] [Full Text] [Related]

  • 3. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
    Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH, Medical Research Council Adult Leukemia Working Party.
    Blood; 2001 Sep 01; 98(5):1312-20. PubMed ID: 11520776
    [Abstract] [Full Text] [Related]

  • 4. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
    Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB 8461).
    Blood; 2002 Dec 15; 100(13):4325-36. PubMed ID: 12393746
    [Abstract] [Full Text] [Related]

  • 5. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
    Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S.
    Leukemia; 2001 Jun 15; 15(6):903-9. PubMed ID: 11417475
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
    Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR.
    Blood; 2000 Dec 15; 96(13):4075-83. PubMed ID: 11110676
    [Abstract] [Full Text] [Related]

  • 11. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).
    Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T, Weltermann A, Fonatsch C, Haas OA, Mannhalter C, Lechner K, Jaeger U.
    Hematol J; 2002 Dec 15; 3(6):283-9. PubMed ID: 12522450
    [Abstract] [Full Text] [Related]

  • 12. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint.
    Archimbaud E, Charrin C, Magaud JP, Campos L, Thomas X, Fière D, Rimokh R.
    Leukemia; 1998 Jan 15; 12(1):25-33. PubMed ID: 9436917
    [Abstract] [Full Text] [Related]

  • 13. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Medical Research Council Leukaemia Working Parties.
    Grimwade D, Walker H, Oliver F, Wheatley K, Clack R, Burnett A, Goldstone A.
    Bone Marrow Transplant; 1997 Jun 15; 19(11):1117-23. PubMed ID: 9193755
    [Abstract] [Full Text] [Related]

  • 14. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C, Lenormand B, Bastard C, Boulet D, Lesesve JF, Callat MP, Stamatoullas A, Monconduit M, Tilly H.
    Am J Hematol; 1996 Nov 15; 53(3):175-80. PubMed ID: 8895688
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.
    Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F, Stoppa AM, Marit G, Molina L, Michallet M.
    Leukemia; 1995 Sep 15; 9(9):1491-8. PubMed ID: 7658718
    [Abstract] [Full Text] [Related]

  • 16. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
    Rossi G, Pelizzari AM, Bellotti D, Tonelli M, Barlati S.
    Leukemia; 2000 Apr 15; 14(4):636-41. PubMed ID: 10764149
    [Abstract] [Full Text] [Related]

  • 17. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.
    Cancer Res; 1998 Sep 15; 58(18):4173-9. PubMed ID: 9751631
    [Abstract] [Full Text] [Related]

  • 18. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse.
    Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kahls P, Mitterbauer G, Jäger U, Kainz B, Geissler K, Valent P, Sperr WR, Knöbl P, Schwarzinger I, Gleiss A, Lechner K.
    Leukemia; 2004 Feb 15; 18(2):293-302. PubMed ID: 14671635
    [Abstract] [Full Text] [Related]

  • 19. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W.
    J Clin Oncol; 2003 Jan 15; 21(2):256-65. PubMed ID: 12525517
    [Abstract] [Full Text] [Related]

  • 20. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
    Chang M, Raimondi SC, Ravindranath Y, Carroll AJ, Camitta B, Gresik MV, Steuber CP, Weinstein H.
    Leukemia; 2000 Jul 15; 14(7):1201-7. PubMed ID: 10914543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.